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Understanding how viruses subvert host immunity
and persist is essential for developing strategies to
eliminate infection. T cell exhaustion during chronic
viral infection is well described, but effects on anti-
body-mediated effector activity are unclear. Herein,
we show that increased amounts of immune com-
plexes generated in mice persistently infected with
lymphocytic choriomeningitis virus (LCMV) sup-
pressed multiple Fcg-receptor (FcgR) functions.
The high amounts of immune complexes suppressed
antibody-mediated cell depletion, therapeutic anti-
body-killing of LCMV infected cells and human
CD20-expressing tumors, as well as reduced
immune complex-mediated cross-presentation to
T cells. Suppression of FcgR activity was not due
to inhibitory FcgRs or high concentrations of free
antibody, and proper FcgR functions were restored
when persistently infected mice specifically lacked
immune complexes. Thus, we identify a mechanism
of immunosuppression during viral persistence with
implications for understanding effective antibody
activity aimed at pathogen control.
INTRODUCTION
Antibodies are critical for eliminating viral infection, preventing
re-infection, and controlling persistent virus infections (Hangart-
ner et al., 2006). Antibodies (Abs) prevent de novo cell infection
by neutralizing the interaction between a virus and its cellular re-
ceptor (neutralizing; nAbs), opsonizing free virions, and targeting
viral proteins on the surface of infected cells to facilitate cell-
killing by either NK cells (Ab-dependent cellular cytotoxicity;
ADCC) or phagocytic cells (Ab-dependent cellular phagocytosis;
ADCP) (Nimmerjahn and Ravetch, 2008). Persistent virus replica-
tion is associated with multiple T cell and B cell dysfunctions that
impede control of infection, but little is known about potential Ab
defects during viral persistence (Hangartner et al., 2006; Moir
and Fauci, 2009). Considering the importance of antiviral Absin maintaining control of persistent infections and their potential
therapeutic value, diminished Ab efficacy could substantially
impact productive immune responses (Burton et al., 2012). In
many persistent virus infections such as human immunodefi-
ciency virus (HIV) and lymphocytic choriomeningitis virus
(LCMV) in mice, nAbs are low and late to emerge (Hangartner
et al., 2006), yet non-nAbs can still exhibit immune pressure,
suggesting that non-nAbs can perform functions important for
Ab-mediated control of persistent virus infection. Consistent
with this notion, the contribution of non-nAbs toward control of
infection is beginning to emerge, and although their exact mech-
anism of antiviral activity is unclear, it is surmised that ADCP and/
or ADCC are critical (Burton, 2002; Chung et al., 2014). Thus, a
defect in Ab function could have a detrimental impact on the
immune system’s ability to target and kill infected cells, further
contributing to immunosuppression and ineffective viral control.
In addition to their endogenous antiviral roles, therapeutic
administration of Abs (particularly nAbs) has shown efficacy to
limit virus replication in multiple models of persistent infection
(Barouch et al., 2013; Burton et al., 2012; Klein et al., 2012;
Law et al., 2008; Shibata et al., 1999; Trkola et al., 2005). Sepa-
rate from neutralization capacity, both nAbs and non-nAbs can
inhibit viral replication at its source by targeting and killing
virus-infected cells through Fcg-receptor (FcgR)-dependent
effector mechanisms. Further, antigen-presenting cells (APCs)
internalize antigen-Ab immune complexes (ICs) via FcgRs to
then initiate T cell responses against virus escape mutants and
co-infecting pathogens. Similarly, FcgRs on follicular dendritic
cells (FDCs) help to retain ICs for B cell selection and affinity
maturation to produce highly effective antibodies (Guilliams
et al., 2014). Although dysfunctions in T cell and B cell responses
are hallmarks of persistent viral infections (Moir and Fauci, 2009;
Wherry, 2011), whether Ab effector functions such as ADCC,
ADCP, or cross-presentation are affected remains unclear. We
previously observed that substantially higher amounts of cell-
depleting Abswere required to deplete target cells during persis-
tent LCMV infection compared to in naive mice (Fahey et al.,
2011), suggesting a functional suppression of Ab activity during
viral persistence. Further, in initial experiments using less effec-
tive nAbs than used now, it was observed that nAbs could not
control HIV infection in humans despite their ability to neutralize
patient samples ex vivo (Mehandru et al., 2007; Poignard et al.,
1999; Trkola et al., 2005). Upon subsequent analysis, it wasImmunity 42, 379–390, February 17, 2015 ª2015 Elsevier Inc. 379
estimated that at least 103 more Ab would be required to
achieve a 50% response in HIV-infected patients (Huber et al.,
2008; Trkola et al., 2008), suggesting diminished Ab effector ac-
tivity during persistent infections of humans as well. Herein, we
demonstrate that high amounts of ICs generated during viral
persistence suppress FcgR-dependent, Ab-mediated effector
functions including the killing of infected cells and antigen pre-
sentation for T cell activation, thus compounding the overall
immunosuppression that potentiates persistent viral infection.
RESULTS
Suppression of Ab-Mediated Cell Killing during
Persistent Virus Infection
To determine whether persistent virus infection suppresses Ab
effector activity, we utilized the LCMVmodel of murine infection.
Infection with the Armstrong (Arm) variant of LCMV induces a
robust immune response that clears the viruswithin 2weeks after
infection. Infection with the LCMV variant Clone 13 (Cl13) estab-
lishes a persistent infection due to increased virus replication and
receptor affinity that help to outcompete the developing immune
response, thereby inducing immunosuppression, T cell exhaus-
tion, and B cell dysfunctions (Ahmed et al., 1984; Fahey and
Brooks, 2010; Hangartner et al., 2006). To examine Ab suppres-
sion, we treated naive and LCMV-Cl13 persistently infectedmice
with high and low doses of two different monoclonal anti-CD4+
T cell-depleting Abs (both of the rat IgG2b isotype). Whereas a
low Ab dose resulted in nearly complete CD4+ T cell depletion
in naive mice, Ab-mediated depletion was suppressed even at
the highest dose administered during persistent infection (Fig-
ures 1A and 1B). Although both Abs were equally effective at
CD4+ T cell depletion in naive mice, only the YTS191 Ab showed
some, but decreased efficacy in LCMVpersistently infectedmice
(Figures 1A and 1B). Together, these data indicate that, similar to
CD8+ T cell exhaustion during persistent virus infection wherein
some antiviral function is retained (Wherry, 2011), Ab depleting
activity is not completely lost but suppressed.
To further explore the suppression of effector Ab function, we
evaluated the efficacy of multiple cell-depleting monoclonal Abs
in naive and LCMV persistently infected mice using Abs of
different isotypes and targeting a variety of cell surface antigens.
Unlike naive mice wherein Ab-mediated depletion was highly
efficacious, Ab effector function was suppressed in LCMV
persistently infected mice treated with CD8+ T cell, B cell, or
platelet-depleting Abs (Figure 1C, Table S1, and data not
shown). Similarly, Ab immunotherapy with Rituximab to target
huCD20-expressing murine tumor cells was protective in naive
mice at the dose given, whereas four out of five persistently in-
fected mice rapidly formed tumors (Figure 1C). Thus, the consis-
tently observed decrease in cell-depleting capacity of Abs from
various species, of multiple isotypes, and affecting various tar-
gets indicates that inherent Ab effector activity is suppressed
during persistent virus infection.
High Concentrations of ICs Impede Ab Effector Activity
during Viral Persistence
To address whether the suppression of Ab function also occurs
during acute viral infection, we infected mice with LCMV-Arm
(acute) or LCMV-Cl13 (persistent) and then treated with anti-380 Immunity 42, 379–390, February 17, 2015 ª2015 Elsevier Inc.CD4+ T cell depleting Abs. Compared to naive mice, low sup-
pression of Ab effector function was observed at day 8 in both
LCMV-Arm and Cl13 infections (Figure 2A). At day 45 of
LCMV-Arm infection (30 days post viral clearance), Ab-mediated
depletion was effective, whereas it remained substantially sup-
pressed in persistently infected mice (Figure 2A), indicating
that Ab effector suppression is present early in viral infection
but increases only during the course of persistent infection.
Persistent viral infections such as HIV, hepatitis B and C vi-
ruses (HBV, HCV), and LCMV are characterized by high amounts
of ICs and non-virus-specific immunoglobulin G (IgG) (often
termed hypergammaglobulinemia; hyperIgG; Figure 2B) (Hang-
artner et al., 2006; Hunziker et al., 2003; Moir and Fauci, 2009).
Although LCMV-specific Abs are detected in the plasma of ani-
mals with acute and persistent infections by day 8, they remain
at much lower concentrations during persistent infection despite
high titers of virus present (Figure 2B). In contrast, as the infec-
tion progresses, total plasma IgG and IC concentrations are
higher in animals with persistent compared to acute infections
(Figures 2B and 2C).
To address the role of hyperIgG-ICs in the suppression of Ab
effector function, we tested cell-depleting activity in three sepa-
rate cohorts of mice that maintain the same high titers of persis-
tent viral replication, but have greatly reduced Ab concentrations
(termed low Ab mice; Figure S1A and S1B). We used: (1) B cell-
deficient mice (mMT) that cannot produce Ab; (2) mice express-
ing a transgenic non-LCMV-specific B cell receptor against
hen egg lysozyme (HEL-tg mice) that do not see cognate antigen
and thus do not produce Ab; and (3) mice that are CD4+ T cell-
depleted prior to infection and lack sufficient B cell help to pro-
duce Ab (Figures S1A and S1B). For the mice that were CD4+
T cell-depleted prior to infection to achieve low Ab concentra-
tions, anti-CD8+ T cell Abs were used for subsequent depletion.
In contrast to persistently infected wild-type (WT) mice wherein
Ab effector function is suppressed (termed high Ab mice), Ab-
mediated depletion was effective in all low Ab mice despite the
same amount of virus replication (Figure 3A and S1A), indicating
that the high amount of Ab and/or ICs lead to the suppression of
Ab effector activity.
To confirm that the failure to deplete cells in persistent infec-
tion was not due to intrinsic resistance of the target cells them-
selves or an inability of antibodies to reach their targets, we
transferred CD4+ T cells from persistently infected high Ab
mice into infection matched low Ab mice. Transferred CD4+
T cells from high Ab mice were effectively targeted and depleted
in low Ab mice, highlighting that the lack of depletion in high Ab
mice is not due to cell-intrinsic differences (Figure 3B). Further,
despite accelerated Ab catabolism in persistently infected high
Ab mice (Figure 3C), target cells were completely coated with
depleting Ab for at least 5 days following treatment (Figure S1C),
and depletion did not occur early then reconstitute in high Ab
mice nor was depletion enhanced by multiple treatments with
depleting Abs (Figure S1D). Therefore, binding defects,
increased target turnover from the cell surface, or rapid repopu-
lation of target cells were not responsible for the observed
decrease in immune-mediated cell depletion.
Interestingly, early (day 8) in acute LCMV-Arm infection, the
amount of ICs is increased compared to persistent LCMV-
Cl13 infection corresponding to a 5%–10% decrease in Ab
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Figure 1. Persistent Virus Infection Suppresses Ab-Mediated Cell Depletion
(A) Uninfected and mice persistently infected with LCMV-Cl13 for 21 days received low dose (LD; 100 mg) or high dose (HD; 1 mg) of isotype or anti-CD4+ T cell-
depleting Ab (clone GK1.5 or clone YTS191; both rat IgG2b). Flow plots represent the frequency and graphs indicate the number ± SD of CD4+ T cells in the blood
5 days after Ab treatment. Ab clones recognizing separate epitopes than the depleting antibodies were used for staining.
(B) Graph represents the percent depletion ± SD of the number of splenic CD4+ T cells 5 days after Ab treatment relative to isotype-treated mice. Percent
depletion was calculated by dividing the number of CD4+ T cells following depletion by the average number of CD4+ T cells present in isotype treated mice.
Isotype is set to 100.
(C) Uninfected (black) and mice persistently infected with LCMV-Cl13 (red) for 21 days received isotype or anti-CD20 B cell-depleting Ab (clone MB20; mouse
IgG2a/c), platelet-depleting Ab (clone 6A6; mouse IgG2a/c) or huCD20+ EG7 tumor cells followed by anti-huCD20 (Rituximab; human IgG1). Flow plots represent
the percent of B cells (B220+) in the blood, platelets determined as CD41+, CD61+ per mL blood, and tumor burden represented as the percent of mice protected
from tumor formation following treatment (survival). Note, all mice treated with non-tumor-specific isotype-matched Ab (Herceptin; human IgG1) developed
tumors (data not shown).
*p < 0.05. **p < 0.05 compared to the same condition in naive mice. Data are representative of two or more independent experiments using three to five mice per
group. See also Table S1.
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Figure 2. Suppressed Ab-Mediated Cell Depletion in Persistent, but Not Acute LCMV Infection
(A) Naive mice or mice infected with LCMV-Arm or LCMV-Cl13 8 or 45 days earlier received 100 mg of isotype or anti-CD4 (clone GK1.5) Ab. Graphs represent the
number ± SD of CD4+ T cells 5 days after Ab treatment. The number above each bar represents percent depletion versus isotype.
(B) Graphs represent the concentration ± SD of total IgG (left) and LCMV-specific IgG (middle) in the plasma, and splenic virus titers (right) are represented at the
indicated time points after infection with LCMV-Arm (black) and LCMV-Cl13 (red). Assay limit of detection (dotted line).
(C) Graph represents the concentration ± SD of ICs (black) or total IgG (Ab+IC; gray) detected in the plasma of naivemice (N) and at the indicated time points after
LCMV-Arm (A) or Cl13 (Cl) infection.
*p < 0.05 Amount of ICs Arm versus Cl13. **p < 0.05 total Ab+IC Arm versus Cl13. Data are representative of two or more independent experiments using three to
five mice per group.
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Figure 3. High Amounts of ICs Suppress Effector Ab Activity during Viral Persistence
(A) LCMV-Cl13 infectedWT, B cell-deficient (mMT), B cell transgenic (HEL-tg) mice, or mice CD4+ T cell-depleted prior to infection received 100 mg of isotype, anti-
CD4 (cloneGK1.5), or anti-CD8 (clone53.6.72) depletingAb21or 30days after infection. Themice thatwereCD4+Tcell-depletedbefore infection receivedanti-CD8
Abat the30day timepoint. Flowplots indicate thepercent andgraphs represent thenumber±SDofCD4+ orCD8+ Tcells in the blood5days followingAb treatment.
(B) CD19, CD11b, and CD8-depleted splenocytes from LCMV-Cl13 persistently infected CD45.1+ mice (D21 after infection) were transferred into infection
matched CD45.2+ low Abmice (CD4+ T cell-depleted prior to infection) or high Abmice. Mice received 100 mg of isotype or anti-CD4 Ab (clone GK1.5). Flow plots
indicate the percent and graphs represent the number ± SD of donor CD4+ T cells (B220, Thy1.2+, CD4+, CD45.1+) remaining in the blood 2 days following Ab
treatment.
(C) Naive (black) or LCMV-Cl13 infected (day 21 after infection; red) WT mice received 1.5 mg of Rituximab. Mice were bled at the indicated times after treatment
and human IgG (Rituximab) concentration ± SD was measured in the plasma by ELISA.
(D) LCMV-Cl13 infected low Ab mice (CD4+ T cell-depleted prior to infection) were left untreated or treated daily with 1 mg of anti-OVA Ab alone or 1 mg of Ova
protein/anti-OVA ICs. One day after the first treatment, mice received 100 mg of isotype or anti-CD8 Ab (clone 2.43). Graph represents the number ± SD of CD8+
T cells in the spleen 5 days after depletion.
(E) Peritoneal macrophages from LCMV-Cl13 infected low Abmice (CD4+ T cell-depleted prior to infection) were incubated with CD45.1+ CD4+ T cells and isotype
(light gray) or anti-CD4 Ab (clone GK1.5) in the presence of increasing concentrations of anti-Ova Ab alone (black) or anti-Ova/OVA ICs (gray). Graph represents
the number of CD45.1+ CD4+ T cells one day later.
*p < 0.05. Data are representative of two or more independent experiments using three to five mice per group. See also Figure S1.
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depletion efficacy in the acute infection (Figures 2A and 2C).
However, as persistent infection progresses, the concentration
of ICs increases and Ab effector activity is lost. In contrast,
depletion efficacy remains high following the resolution of acute
LCMV infection where IC concentrations are low (Figures 2A and
2C), suggesting that ICs are responsible for the suppression of
Ab depletion activity. To conclusively differentiate the relative
contributions of free Ab alone versus ICs to the suppression of
depleting Ab effector function, we treated persistently infected
low Ab mice with anti-Ovalbumin (Ova) Ab alone or anti-Ova-
Ova protein ICs. Although in these experiments the amount of
total Ab achieved was much lower than that observed in high
Ab mice, the ICs suppressed Ab-mediated depletion, whereas
the Ab alone at these low concentrations had little inhibitory
effect (Figure 3D). Even treating low Ab mice with 10 times
more free Ab still was not sufficient to inhibit Ab effector activity
(Figure S1E) and ICs, but not free Ab readily prevented cell
depletion in ex vivo assays (Figure 3E). Together, these data indi-
cate that it is the high concentration of ICs and not free Ab during
persistent infection that suppresses effector Ab activity.
High Amounts of ICs Impede Macrophage-Mediated
Phagocytosis
Ab-mediated depletion can occur via complement-dependent
cytotoxicity, ADCC by NK cells, or ADCP by macrophages, den-
dritic cells (DC), and neutrophils (Jiang et al., 2011; Nimmerjahn
and Ravetch, 2008). We used the low Ab mice where cell deple-
tion is efficacious despite persistent virus replication (Figure 2C)
to determine the effector mechanisms impeded by the high con-
centrations of ICs during viral persistence. Neither inactivation of
complement components using cobra venom factor (CVF) nor
the removal of NK cells or neutrophils led to a decrease in Ab-
mediated cell depletion (Figures S2A–S2C), indicating that the
complement pathway, ADCC by NK cells, or ADCP by neutro-
phils are not involved. On the other hand, treatment of persis-
tently infected low Ab mice with clodronate-filled liposomes to
deplete phagocytic cells (i.e., macrophages andDC) suppressed
Ab-depleting activity (Figure 4A and S2D), indicating that the
high concentration of ICs primarily suppress Ab-mediated
phagocytic activity during persistent virus infection.
Both macrophages and DC can be phagocytic (Guilliams
et al., 2014) and were depleted by clodronate treatment (Fig-
ure S2D). To differentiate the role of macrophages and DC, we
performed ex vivo phagocytosis assays with sorted splenocytes
from persistently infected low Ab mice. Ab-mediated depletion
was observed using total splenocytes (Figure 4B) or DC-
depleted splenocytes (Figure S3A), but was lost when macro-
phages were depleted (Figure 4B). Similarly, no effect on
Ab-mediated depletion was observed when DC were selectively
depleted in vivo (Figure S3B). Taken together, these data
demonstrate that macrophage-mediated phagocytosis is sup-
pressed by the high amounts of ICs generated during persistent
viral infection.
FcgR Blockade Is Responsible for Suppression of
Macrophage-Mediated Phagocytosis
We next determined whether the decreased ADCP was due to
fundamental alterations in macrophage function or a physical
blockade of phagocytic activity. ADCP is mediated by Ab384 Immunity 42, 379–390, February 17, 2015 ª2015 Elsevier Inc.engagement with activating FcgR on macrophages (FcgRI,
FcgRIII, FcgRIV in mice; FcgRI, FcgRIIA, FcgRIIC, FcgRIIIA in
humans), while engagement with the inhibitory receptor FcgRIIB
inhibits phagocytic activity (Nimmerjahn and Ravetch, 2008).
Similar numbers ofmonocytes andmacrophageswere observed
in the blood and spleens of persistently infected high and low Ab
mice (Figure S3C). Further, no decrease (and in most cases an
increase) in activating FcgR expression was observed in both
high and low Ab mice compared to naive controls (Figure 4C),
indicating that the suppression was not due to decreases in
FcgR expression. Interestingly, although inhibition mediated by
FcgRIIB is an immunosuppressive mechanism in some situa-
tions (Nimmerjahn and Ravetch, 2008), persistent infection of
FcgRIIB-deficient (high Ab) mice did not rescue the suppression
of Ab function (Figure 4D), indicating that macrophage suppres-
sion during persistent viral infection is not due to a decreased
ratio of activating to inhibitory receptors or increased FcgRIIB
signaling.
We observed increased amounts of IgG on the surface ofmac-
rophages in persistently infected high Ab mice compared to low
Ab or naive mice (Figure 5A) suggesting that surface-bound Ab
physically impedes effector Ab activity. Importantly, the amount
of surface IgG during persistent infection compared to naive
mice is not solely due to increased FcgR expression because
low Ab mice also have greatly increased FcgR expression
compared to naive mice (and similar/higher than high Ab mice),
but maintain low amounts of circulating and surface-bound IgG
similar to naive mice. To address whether the suppression of
macrophage activity was due to permanent cellular inhibition
or a physical blockade of FcgR interactions, splenocytes and
peritoneal macrophages were isolated from high Ab mice,
washed to remove FcgR-bound Ab-ICs, and allowed time to
recover (Figure 5B and data not shown). Despite the inhibition
in vivo, splenic and peritoneal macrophages from the high Ab
mice now exhibited similar effector activity to macrophages
from low Ab mice ex vivo (Figures 5B and 5C). Importantly, the
Ab effector function was lost when these phagocytic cells lacked
activating FcgRs (Figure 5C). Thus, the suppression of Ab
effector function is not a permanent functional macrophage
defect but instead results from blockade of surface FcgRs by
the high amount of ICs present during persistent infection.
Multiple FcgR-Mediated Effector Functions Are
Suppressed during Viral Persistence
Abs mediate multiple antiviral functions during infection
including virus neutralization, the opsonization/killing of infected
cells, and FcgR-mediated IC internalization by APCs for cross-
presentation and T cell activation. Thus, suppression of Ab
effector activity could have many ramifications toward ongoing
and de novo immune responses. To determine the impact of
Ab suppression toward virus neutralization, we used the M1
variant of LCMV (LCMV-M1) in which a two amino acid change
engineered into the glycoprotein (GP) of LCMV-Cl13 (Osokine
et al., 2014) renders it susceptible to neutralization by the anti-
LCMV KL25 antibody, unlike the parental LCMV-Cl13 strain
that is not neutralized or bound by KL25 (Figure S4). High Ab
and low Ab cohorts of mice were generated using persistent
infection with LCMV-M1 and then treated with KL25 Ab
21 days after infection. Seven days following KL25 Ab treatment,
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Figure 4. Macrophages Mediate Cell-
Depleting Ab Function
(A) LCMV-Cl13 infected low Ab (HEL-tg) micewere
treated 21 days after infection with clodronate-
filled (Clod) liposomes or control (Cont) liposomes.
One day later, mice received 100 mg of isotype or
anti-CD4 Ab (clone GK1.5). Flow plots indicate the
percent and the graph represents the number ±
SD of CD4+ T cells in the blood 5 days after Ab
treatment.
(B) T cell and B cell-depleted splenocytes pooled
from low Ab (CD4+ T cell-depleted before infec-
tion), CD45.1+ mice containing macrophages or
further depleted of macrophages were mixed with
CD45.2+ CD4+ T cells for an ex vivo phagocytosis
assay. Cultures were given isotype or anti-CD4 Ab
(clone GK1.5) and the frequency and number of
CD45.2+ CD4+ T cells was quantified in the cul-
tures 2 days later.
(C) Graphs represent the gMFI of the indicated
FcgR on macrophages [B220, Thy1.2, Ly6G,
NK1.1, CD11c(mid-lo), F4/80+, CD11b+] and den-
dritic cells [B220, Thy1.2, Ly6G, CD11c(hi)]
from naive (N), and day 21 after LCMV-Cl13
infection of mice that were CD4+ T cell-depleted
prior to infection (low Ab; L) or left undepleted (high
Ab; H).
(D) LCMV-Cl13 infected FcgRIIB-deficient mice
were treated 21 days after infection with 100 mg of
isotype or anti-CD4 Ab (clone GK1.5). Flow plots
indicate the percent and graphs represent the
number ± SD of CD4+ T cells in the blood and
spleen 5 days following Ab treatment.
*p < 0.05. Data are representative of two or more
independent experiments using three to five mice
per group. See also Figures S2 and S3.viremia was undetectable in both high Ab and low Ab mice (Fig-
ure 6A), demonstrating that virus neutralization with the KL25 Ab
is effective in persistent virus infection.
Another main function of virus-specific Abs is the binding of
viral proteins expressed on the surface of infected cells to initiate
killing via FcgR interactions. To address whether the high
amount of ICs generated during persistent virus infection sup-
press Ab-mediated killing of infected cells, we infected DC
with LCMV-M1, transferred the infected cells into LCMV-Cl13
persistently infected low Ab or high Ab mice, and then treated
the mice with isotype control or KL25 Ab. In this way, the trans-
ferred cells were targeted by the KL25 Ab while not affecting
endogenous titers of LCMV-Cl13. The mice were also CD8+
T cell-depleted prior to infection to prevent cytotoxic lymphocyte
(CTL)-mediated killing of the transferred infected cells. Within
6 hr after transfer, KL25 Ab treatment reduced the number of in-Immunity 42, 379–390,fected DC by 50% in low Ab mice, but
was ineffective in the high Ab mice (Fig-
ure 6B). Since the KL25 Ab effectively
binds and neutralizes LCMV-M1 in
persistently infected high Ab mice (Fig-
ure 6A andS4), these data further demon-
strate that even highly potent Abs exhibit
suppression of ADCP activity and are
diminished in their ability to kill infectedcells when high concentrations of ICs are present during
persistent viral infection.
Interestingly, elevated concentrations of IgG are also de-
tected on DC in persistently infected high Ab mice (Figure 6C),
suggesting that their FcgR-mediated functions might also be
suppressed. A major FcgR-mediated function of DC is cross-
presentation of antigen to prime and sustain T cell activity
(Platzer et al., 2014; Regnault et al., 1999). To address the sup-
pression of FcgR-mediated cross-presentation by APC during
persistent infection, we transferred CFSE-labeled, OVA-specific
CD8+ T cells (OT-I) into high or low Ab mice persistently infected
with LCMV-Cl13 and then primed them with either Ova protein
alone or Ova-anti-Ova ICs. In both cohorts, Ova alone failed
to notably prime CD8+ T cell responses despite the ongoing
inflammation of the persistent virus infection (Figure 6D).
In contrast, Ova-anti-Ova ICs effectively primed OT-I T cellFebruary 17, 2015 ª2015 Elsevier Inc. 385
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Figure 5. High Amounts of ICs Impede
FcgR-Mediated Phagocytosis
(A) Surface-bound mouse IgG on macrophages
of naive mice (black line) and day 21 after LCMV-
Cl13 infection of mice that were CD4+ T cell-
depleted prior to infection (low Ab; gray) or left
undepleted (high Ab; black).
(B) Histogram shows surface bound mouse-IgG
ex vivo on splenic macrophages from low Ab and
high Ab mice following enrichment by B cell and
T cell depletion. These sorted splenocytes from
low Ab and high Abmice weremixed with CD45.1+
CD4+ T cells in the presence of isotype or anti-CD4
Ab (clone GK1.5) for an ex vivo phagocytosis
assay. Graphs represent the number of CD45.1+
CD4+ T cells 2 days after culture.
(C) Peritoneal macrophages from CD45.2+
persistently infected FcgR-deficient and WT
mice (both high Ab) and low Ab WT mice (CD4+
T cell-depleted prior to infection) were mixed with
CD45.1+ WT CD4+ T cells in the presence of iso-
typeor anti-CD4Ab (cloneGK1.5). Flowplots show
the percent and graphs represent the number of
CD45.1+ CD4+ T cells in the culture 1 day later.
Data are representativeof twoormore independent
experiments using three to five mice per group.expansion in persistently infected low Ab mice, whereas priming
was almost entirely suppressed in high Ab mice (Figure 6D).
Thus, the high concentrations of ICs generated during persis-
tent infection suppress FcgR-mediated cross-presentation by
APCs to limit de novo CD8+ T cell responses to secondary
antigens.
DISCUSSION
Despite the many immune dysfunctions associated with persis-
tent viral infections, a specific impact on inherent Ab effector ac-
tivity has not been observed. Herein, we identify a previously
unrecognized mechanism of immunosuppression during persis-
tent virus infection in which the elevated concentrations of ICs
directly impede macrophages and DCs to suppress multiple
FcgR-dependent Ab effector functions. Similar to naive mice
(Biburger et al., 2011), cell-depletion capacity during persistent
infection was primarily dependent on phagocytosis by macro-
phages and not other Ab-mediated mechanisms of cell killing.
Macrophage suppression was reversed when cells were
removed from their high IC environment and could be inhibited
when ICs were added back, demonstrating that the macro-
phages were not permanently dysfunctional, and that high con-
centrations of ICs were continually blocking surface FcgRs and
inhibiting their activity in vivo. Importantly, we did not observe
a notable suppression of other Ab functions such as effective
target binding, receptor blockade (Barber et al., 2006; Brooks
et al., 2006; Teijaro et al., 2013; Wilson et al., 2013), or neutrali-
zation of infectious virus, suggesting that the non-FcgR-medi-
ated functions of Abs might not be affected. On the other
hand, functions that rely on FcgRs (including a component of
the neutralizing capacity; DiLillo et al., 2014) may be compro-
mised by ICs generated during ongoing persistent virus replica-
tion and affect both endogenous and therapeutic immune
control of infection.386 Immunity 42, 379–390, February 17, 2015 ª2015 Elsevier Inc.The elevated total IgG concentration during persistent infec-
tion might increase competition for the neonatal Fc receptor
(FcRn) responsible for salvaging Abs fromdegradation, account-
ing for the increased loss of non-replenished, adoptively trans-
ferred antibody or outcompeting other antibodies present in
relatively low amounts. This might then contribute to both the
low LCMV-specific Ab titers maintained throughout infection
and the shorter duration of vaccination specific antibodies
observed in HIV-infected patients (Miotti et al., 1989; Nielsen
et al., 1998; Roopenian and Akilesh, 2007). Our results indicate
that high doses of potent nAbs can still be efficacious during
persistent infections, but their ADCP activity is suppressed
rendering them less effective at killing infected cells. Administra-
tion of higher doses of Ab enhanced cell-depleting activity dur-
ing persistent infection (although they were still suppressed).
Consistent with this, Rituximab immunotherapy is administered
at high doses over multiple treatments and is generally effective
in HIV-infected individuals (Sparano et al., 2010). Moreover, the
multiple mechanisms through which Rituximab can kill B cells
in addition to ADCP might also contribute to the efficacy of Rit-
uximab in the presence of persistent infections (Jiang et al.,
2011). Thus, our data demonstrate that not all Ab functions are
lost and depleting activity is not entirely absent, just substantially
diminished. This similar immunosuppression is observed with
CD8+ T cells during many persistent virus infections wherein
they still retain some antiviral function, but are insufficient to
purge the infection. As a result, in conjunction with diminished
T cell function, decreased Ab effector activity could contribute
to the overall immune suppression and dysfunction that enables
viral persistence.
Our data indicate that the broad spectrum of Ab functions that
rely on FcgR interactions will be compromised during persis-
tently viremic infections that generate high concentrations of
ICs. Not only is targeting and killing of infected cells suppressed,
but Ab-mediated cross-presentation to prime CD8+ T cell
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Figure 6. Suppression of Ab Effector Activity Diminishes Killing of Infected Cells and IC-Mediated Cross-Priming of T Cells
(A) High Ab mice (WT) and low Ab mice (CD4+ T cell-depleted prior to infection) were persistently infected with the KL25 neutralization-sensitive LCMV-M1 (see
Figure S4). On day 21 after infection, mice received 250 mg of isotype or anti-LCMV KL25 Ab. Graphs represent infectious virus from the plasma before (day 20)
and 7 days after isotype or KL25 treatment.
(B) LCMV-M1-infected, GFP+ DC (KL25 targets) were transferred into LCMV-Cl13 persistently infected high Ab mice and low Abmice (CD4+ T cell-depleted prior
to infection). All mice were CD8+ T cell-depleted prior to infection. Transferred DCwere 99% infected (data not shown). Mice received 250 mg of isotype Ab or anti-
LCMV-M1 KL25 Ab and the graph represents the number ± SD of targets in the spleen 6 hr following Ab treatment.
(C) Surface-bound mouse IgG on dendritic cells in naive mice (black line) and LCMV-Cl13 persistently infected low Ab mice (B cell-deficient; gray) and high Ab
mice (black).
(D) CFSE-labeled Ova-specific OT-I CD8+ T cells (CD45.2+) were transferred into CD45.1+ LCMV-Cl13 persistently infected (day 21) high Ab mice or low Abmice
(CD4+ T cell-depleted prior to infection). One day later, mice were given Ova protein alone or anti-Ova Ab followed by Ova protein (to generate ICs). Flow plots
show the percent of OT-I cells in the blood and histograms indicate cell division by CFSE dilution. Graphs represent the number ± SD of OT-I cells measured in the
blood and spleen 3 days after antigen delivery.
*p < 0.05. Data are representative of two or more independent experiments using three to five mice per group. See also Figure S4.responses against secondary antigens is also affected. Since
dendritic cells and macrophages act as APCs following IC inter-
nalization through FcgR (Guilliams et al., 2014), the blockade of
FcgRs could further limit the development of de novo T cell re-
sponses against virus escape mutants or secondary co-infec-tions. Antigen-Ab ICs bound by FcgRs on FDC are critical for B
cell selection, hyper-mutation, and de novo recognition of Ab-
escape viruses by naive B cells (Heesters et al., 2014). Thus,
decreased ability to bind to FDC could affect the developing
and sustained B cell response to persistent viruses. Further,Immunity 42, 379–390, February 17, 2015 ª2015 Elsevier Inc. 387
pre-existing vaccine-induced immunity is compromised during
many persistent infections (De Milito et al., 2004; Stelekati and
Wherry, 2012) and the suppression of FcgR-dependent effector
mechanisms such as killing infected cells, opsonizing virions, or
cross-presenting antigens to T cells could contribute to their
decreased protective capacity. Therefore, the suppression of
Ab-mediated effector activity could undermine many critical im-
mune functions, thereby compounding immunosuppression and
facilitating viral persistence and co-infections.
It is interesting that although suppression of Ab function was
observed for all Abs analyzed, some Abs worked better than
others during persistent virus infection. Both murine and non-
murine Abs were functionally suppressed during persistent
infection despite being highly effective in naive mice, thus
arguing against species-specific differences in FcgR affinity to
explain their loss of efficacy. Restored function of these same
depleting Abs in persistently infected low Ab mice and the ability
to effectively deplete cells transferred from high to low Ab mice
indicate that neither factors secreted during persistent infection
nor intrinsic changes in cell resistance to ADCP are responsible
for the reduced Ab activity. The continued ability of the anti-
LCMV Ab to effectively neutralize virus in vivo, yet lose ADCP ef-
ficacy, further demonstrates that Abs remain intact during
persistent infection and that Ab effector functions can be differ-
entially impacted. Although it is important to note that all Abs
analyzed exhibited decreased activity during viral persistence,
differences in glycosylation, affinity, target-epitope, or ability to
generate ICs might explain why some Abs are more suppressed
than others. Considering the desire to elicit broadly effective Abs
capable of exhibiting multiple effector functions as preventative
and therapeutic vaccines, it will be important in the future to
determine why certain Abs are better able to resist suppression.
Polyclonal B cell activation and hyperIgG production during
persistent viral infections are associated with the accumulation
of auto-antibodies (Hunziker et al., 2003; Massabki et al., 1997;
Zandman-Goddard and Shoenfeld, 2002). Interestingly, using
the platelet-depletion model of idiopathic thrombocytopenic
purpura (ITP), we observe a suppression of autoAb-induced
platelet reduction during persistent LCMV infection when high
concentrations of ICs are present. Similar protection is observed
with high dose IVIG in the treatment of Ab-mediated autoimmune
diseases (Schwab and Nimmerjahn, 2013; Siragam et al., 2005)
and is thought towork through a variety of mechanisms including
the inhibitory FcgRIIB on macrophages (Anthony et al., 2011).
However, in response to IC-mediated suppression of FcgR func-
tion during persistent infection, we did not observe a rescue of
antibody activity in persistently infected FcgRIIB-deficient
mice, although this type of regulation may be important for other
aspects of the immune response including B cell antibody pro-
duction. Interestingly, mouse models and patients with autoim-
mune systemic lupus erythematosus (SLE) exhibit hyperIgG
and a similar defect in Ab-mediated B cell depletion (Ahuja
et al., 2011; Merrill et al., 2010; Sanz and Lee, 2010). Although
SLE is an autoimmune disorder propagated by pathogenic Abs
and IC deposition, the suppression of phagocytic macrophage
function might attenuate further disease through other mecha-
nisms (Ahuja et al., 2011). Thus, it is interesting to speculate
that the suppression of FcgR-mediated function is not entirely
detrimental during viral persistence, but that an important func-388 Immunity 42, 379–390, February 17, 2015 ª2015 Elsevier Inc.tion of the increased Ab observed during persistent infection
might be to suppress excessive immunopathology and potential
autoimmunity from the self-reactive Abs that are generated dur-
ing the response to persistent viruses (Hunziker et al., 2003).
Overall, our results have important implications for under-
standing the ongoing immune response to persistent virus infec-
tions, for pre-existing and de novo vaccine-induced Abs aimed
at controlling these viruses, and for effective responses to sec-
ondary co-infections. Our data indicate that Ab therapies relying
on effector mechanisms beyond neutralization might be sup-
pressed by persistent virus infection. Thus, therapies designed
to overcome this suppression during viral persistence could
increase vaccine-induced immunity and enhance immune con-
trol of both persistent infections and secondary co-infecting
pathogens.
EXPERIMENTAL PROCEDURES
Mice and Virus
C57BL/6 mice were purchased from The Jackson Laboratory or the rodent
breeding colony at UCLA. B cell-deficient (Ighm/; mMT), FcgRIIB-deficient
(Fcgr2b/), B cell transgenic (hen egg lysozyme [HEL] Ab specific), and
CD11c-DTR mice were purchased from The Jackson Laboratory. FcgR-defi-
cient mice (Fcer1g/; lacking FcgRI, III, and IV, but expressing FcgRIIB)
were provided by J. Ravetch (Rockefeller University). Mouse handling con-
formed to the experimental protocols approved by the UCLA Animal Research
Committee (ARC). In all experiments, themicewere infected intravenously (i.v.)
via the retroorbital sinus with 2 3 106 PFU of LCMV-Arm, LCMV-Cl13, or
LCMV-M1. LCMV-M1 was generated as described in Osokine et al. (2014)
through a reverse genetics approach to rescue a recombinant Cl13 virus con-
taining mutations within the GP1 coding region at I118L and S119N. Virus
stocks were prepared and viral titers were quantified as previously described
(Brooks et al., 2005).
In Vivo Cell Depletions
Target cell depletion was performed by intraperitoneal (i.p.) or i.v. injection of
100 mg or 1 mg (unless otherwise stated) of the following Abs: anti-CD4 clone
GK1.5, anti-CD4 clone YTS191, anti-CD8 clone 53.6.72, anti-CD8 clone 2.43,
anti-NK1.1 clone PK136, anti-Ly6G clone 1A8 (BioXcell); anti-mouse CD20
(clone MB20; 50 mg/mouse) and anti-platelet (clone 6A6; 4 mg/mouse); and
anti-human CD20 (Rituximab; 250 mg/mouse). For analysis of CD4+ or CD8+
T cell depletion, cells were gated on NK1.1, Thy1.2+ cells unless otherwise
stated. For the Rituximab protection experiments, uninfected and LCMV-
persistently infected mice were given subcutaneous injections of 5 3 105
EG7 tumor cells expressing human-CD20. At day 1 and 3 after tumor injection,
mice were given 250 mg of Rituximab (i.p.). Tumor growth was monitored until
tumor diameter reached the 10 mm endpoint.
For studies targeting LCMV-infected cells in vivo, the DC cell line DC2.4 was
infected with LCMV-M1 in vitro for 3 days. Greater than 98% of the cells were
infected at the end of the culture (data not shown). The LCMV-M1 infected DC
were then transferred into LCMV-Cl13 infected mice that had been CD8+ T cell
depleted prior to infection (to prevent killing of transferred DCs by LCMV-spe-
cific CTL). 250 mg of isotype or anti-LCMV KL25 Ab were administered 1 hr af-
ter LCMV-M1 infected DC transfer. In vivo depletion was quantified 6 hr after
transfer.
IC Precipitation and In Vivo Treatment
ICs were precipitated from mouse plasma as performed in Lux et al. (2013).
Briefly, mouse plasma was incubated in 8% PEG6000 (IgG IC precipitation)
or 20% PEG6000 (free Ab plus IC precipitation; total IgG) overnight at 4C.
PEG precipitations were spun down at 2000 3 g for 30 min at 4C, washed
once with PEG6000, again isolated at 2000 3 g, and resuspended in warm
PBS. Precipitated IgG was then quantified by ELISA.
In vivo ICs were generated by incubating 1 mg of rabbit anti-chicken egg
albumin Ab (Sigma) and 1 mg of ovalbumin (Ova) protein for 30 min in PBS
at 37C. Low Ab mice were treated i.p. with 1 mg Ab or 1 mg Ova-Ab ICs daily
for 5 days. One day after the first immune complex treatment, mice received
100 mg of anti-CD8 Ab and cell depletion was quantified 5 days later.
Ex Vivo Phagocytosis Assay
Splenocytes isolated on day 21 of LCMV-Cl13 infection were pooled frommul-
tiple mice and then B cell and T cell-depleted using anti-CD19, anti-Thy1.2,
and anti-CD4 magnetic beads (Miltenyi Biotec) and allowed to recover for
1 hr at 37C in complete media. Splenocytes were pooled from multiple
mice for each experiment to obtain enough cells for the ex vivo phagocytosis
assay and experiments were repeated multiple times. B cell/T cell-depleted
splenocytes or peritoneal macrophages were mixed with negatively selected,
naive CD45.1+ CD4 T cell targets at a 100:1 splenocyte:T cell or 50:1 peritoneal
macrophage:T cell ratio. 30 mg/ml of isotype or anti-CD4 (clone GK1.5) Ab
were added to the culture and the number of target cells was assessed by
flow cytometry 2 days later. In some assays, DC or macrophages were
removed using anti-CD11c or F4/80-PE staining followed by anti-PE magnetic
beads, respectively (Miltenyi Biotec).
In Vivo Ab Mediated Cross-Priming
Ova-specific CD8+ OT-I T cell cross-priming was performed as in (Li et al.,
2014). CD45.1+ LCMV-Cl13 infected high and low antibody mice received
2 3 106 CFSE-labeled CD45.2+ OT-I T cells i.v. on day 30 after infection.
One day later, mice received i.v. 150 mg of isotype Ab or rabbit anti-OVA IgG
followed by 2.5 mg of OVA protein 2 hr later.
Statistics
Student’s t tests (two-tailed, unpaired) and two-phase non-linear regression
curve fit analyses were performed using GraphPad Prism 5 software
(GraphPad Software).
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